News-Medical.net reported that Svizera Europe, a global TB supply and distribution company, and the nonprofit TB Alliance are working together to provide new TB drugs for children. At present, no quality-assured drugs are available in the formulations that the World Health Organization (WHO) recommends for treating children with TB. TB Alliance, in partnership with WHO and with funding from UNITAID, has led an initiative to facilitate the development and delivery of appropriate child-friendly formulations for first-line TB treatment of children. The partnership with Svizera is a first step to creating these pediatric TB drugs. Additional work is needed to ensure that the new drugs will reach the children. To this end, TB Alliance is working with WHO, UNITAID, and others to: clarify the global regulatory path for new pediatric TB treatments, and conduct research to analyze patient numbers and the potential size of the market, gaps in programmatic implementation, barriers to market entry, and other data to help ensure a sustainable supply of the appropriate quality-assured child-friendly TB drugs.